ClinicalTrials.gg
Not yet recruitingNCT07337343Updated Jan 13, 2026

Co-Development and Validation of Colonic Symptom Pictograms for Young People

An observational study in Constipation - Functional, Abdominal Pain (AP) and Nausea and Vomitting, sponsored by University of Auckland, New Zealand. Not yet recruiting. Open to participants aged 8 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Auckland, New Zealand · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
8 Years to 17 Years
Sex
All
01

Study summary

Severe constipation affects 10% of children, often leading to significant physical and emotional distress. While constipation is commonly associated with impaired bowel movements, it is fundamentally linked to abnormalities in colonic motility - the coordinated contractions that facilitate passage of stool through the colon and out of the body. Diagnosis of constipation is based upon the Rome IV criteria, which assess symptoms as reported or remembered over the previous 3 months.

However, reporting symptoms experienced can be challenging for children and young people for many reasons, such as the overlap of sensations, including fullness, bloating, and discomfort, and an inability to recall or precisely distinguish and describe what they are feeling.

This study intends to design, develop, and validate symptom pictograms for children aged 8-17 with colonic or lower gut symptoms.

Read the detailed description

Severe refractory constipation affects 10% of children, often leading to significant physical and emotional distress. While constipation is commonly associated with impaired bowel movements, it is fundamentally linked to abnormalities in colonic motility - the coordinated contractions that facilitate passage of stool through the colon and out of the body. Diagnosis of constipation is based upon the Rome IV criteria, which assess symptoms as reported or remembered over the previous 3 months.

However, reporting symptoms experienced can be challenging for children and young people for many reasons, such as an overlap of sensations, such as fullness, bloating, and discomfort, and an inability to recall or precisely distinguish and describe what they are feeling. An earlier study approved by the New Zealand Health and Disability Ethics Committee (HDEC reference 2022 FULL 12705) designed, developed, and validated a set of upper gastric symptom pictograms to help children and young people record their symptoms during a test called body surface gastric mapping (BSGM). The use of these symptom pictograms has enabled improved correlation of gastric activity with symptoms to assist in the diagnostic process.

This study intends to build on this knowledge and apply it to design, develop, and validate symptom pictograms for children aged 8-17 with colonic or lower gut symptoms.

Objective To co-design, develop, and validate a set of pictograms representing lower gastrointestinal (GI) symptoms that are easily understood and useful for children and young people aged 8-17 years. The pictograms will support improved symptom communication, enhance clinical assessment, and be evaluated for comprehension, acceptability, and utility during investigations.

Study Design and Methodology:

A multi-phase, mixed-methods study incorporating participatory co-design, iterative prototyping, and validation testing with children and young people aged 8-17 years.

Study Population Children and young people aged between 8-17-years with and without lower gastrointestinal symptoms.

Participant Numbers Phase One: A review of current guidelines and symptom questionnaires to confirm core colonic symptoms relevant to refractory constipation, and a web-based search for images depicting these symptoms to identify common concepts. Final selection will be confirmed by the research team and clinical advisors.

Phase Two: Co-design. A minimum of 30 children and young people.

Phase Three: Pictogram Development and Refinement based on Phase I, and check the designs for clarity with a group of young people before the validation phase.

Phase Four: Validation: At least 80 children and young people with and without lower gastrointestinal symptoms such as constipation.

Inclusion Criteria For all phases, the main inclusion criteria for all children and young people participants are that they are,

  • aged between 8-17 years,
  • able and willing to complete the tasks, and
  • communicate in English or be supported by a caregiver, whānau (family), or responsible adult to participate

Criteria for Evaluation Phase One: Thematic analysis of symptom concepts and visual ideas, and identification of the symptoms that will be designed and presented visually

Phase Two: Gather pictures of symptoms drawn by young people. Review of symptom concepts drawn by participants, reviewing differences and similarities by different ages, sex, and ethnicity (as appropriate), such as facial expressions, colours, and prompts used. Design new colonic symptom pictograms that reflect the outcome of Phases One and Two.

Phase Three: Confirm the clarity and qualitative feedback on preferred styles and features of the new pictograms.

Phase Four: Following ISO standard 9186, Comprehension Validity (translucency and transparency) and content validity index metrics, the pictograms will be evaluated for understanding and agreement and validated against existing tools.

Statistical Methods Phases Two and Three: A convenience sample will be adopted, so no power analyses have been calculated.

Phase Four: The proposed minimum of 80 participants is expected to be sufficient to test the guessability, translucency, and validity of six to ten pictograms and provide precision about the mean and variance for the consistency, reliability, and construct validity. (Boateng et al. 2018)

Analysis Phase One: A review of common themes, symptom concepts, and visual ideas will be used to identify the relevant symptoms that need to be co-designed.

Phase Two: A review of the common themes, images, and prompts to enable new pictograms to be designed and developed

Phase Three: A review of the responses for each symptom pictogram recognition and understanding.

Phase Four: Descriptive and comparative statistics will be utilised. Translucency will be assessed using a visual analogue scale, ranging from 0 (complete lack of correlation) to 5 (very high correlation agreement). Achieving an agreement of ≥3 is identified as an acceptable level of correlation between the pictogram and its meaning. Validity will be evaluated using the Content Validation Index (CVI) and Pearson's correlation coefficient equations, with internal reliability assessed using Cronbach's α. A CVI greater than 80% and a coefficient level above 0.65 are acceptable.

02

Conditions studied

  • Constipation - Functional
  • Abdominal Pain (AP)
  • Nausea and Vomitting
  • Bloating
  • Flatulence
  • IBS, Constipation Predominant

Keywords

  • children and adolescents
  • pictograms
  • co-design
  • validation
03

In context

Abdominal Pain

387 studies on the registry are indexed under Abdominal Pain; 58 are open to participants now.

This study's planned enrollment of 120 is close to the median of 127 across 80 observational studies indexed under Abdominal Pain.

Browse Abdominal Pain studies →

Lead sponsor

University of Auckland, New Zealand is the lead sponsor of 57 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

International cohort of young people aged 5-17 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children and Young people are aged between 8-17 years,

  • have lower gut or constipation symptoms,
  • can communicate in English or be supported to participate by a caregiver, whānau, or other responsible person. Phase Four will include international invitations to participants with lower gut or constipation symptoms. Healthy volunteers will not be recruited.

Exclusion criteria

Exclusion Criteria:

  • Children and Young people with developmental or cognitive disorder that precludes their ability to understand the study,
  • Children and Young people who do not have access to a digital device with internet connectivity,
  • unable to read English,
  • parent does not consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • children and young people aged 8-17 years

    children and young people aged 8-17 years with lower GI symptoms

    Other: Pictogram comprehension and validation

Interventions

  • OtherPictogram comprehension and validation

    This study aims to codesign and validate Colonic Symptom Pictograms for use with Young People to support them in distinguishing and reporting the symptoms they experience.

06

What researchers measure

Primary outcomes

  1. Validation of each Pictogram

    We hypothesize that the new colonic pictogram-based symptom reporting will demonstrate equivalent or superior validity and reliability compared to traditional questionnaire-based methods for reporting constipation symptoms in young people. Specific analyses will be to evaluate the pictograms for comprehension, translucency, face validity, construct validity, and convergent and divergent validity. * Comprehension: responses will be measured using a scale from 1= correct , 4= correct and 5 = did not answer. * Translucency: Likert rating scale to report how well participants report the pictograms reflect the intended symptoms Convergent: Using Rome IV Section B responses will be compared to the correct pictogram to assess correlations Divergent: A lower relationship between pictogram comprehension and PedsQL Oral Health questionnaire will be assessed Concurrent: PedQL answers will assess the association between accruated identifying the pictograms and health outcomes

    Time frame: Analyses will be undertaken once the last participant (80th) has completed the online survey. This is anticipated to occure 6 months fro start of the study,

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — During the study, data may be collected from participants who identify, for example, as Māori (indigenous population of New Zealand). Providing insights and information to research is a tāonga (treasure) and will be treated accordingly. The research team aims to ensure data sovereignty in light of, for example, the global directives on Indigenous rights and local treaties such as Te Tiriti o Waitangi in Aotearoa/New Zealand. We will not routinely make IPD data available. However, we will consider requests where the proposal meets international guidelines to ensure that datasets are analysed according to the data governance of the respective cultures, such as Tikanga Māori in New Zealand.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

Of 28 non-industry observational studies under Abdominal Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 37 studies reached it within 16 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Jan 13, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07337343
Lead sponsor
University of Auckland, New Zealand
Responsible party
Gayl Humphrey (Dr, University of Auckland, New Zealand) — Principal investigator
First posted
Jan 13, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Gayl Humphrey, PhD
Contact
g.humphrey@auckland.ac.nz
+64 211100901

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion